643 related articles for article (PubMed ID: 12658281)
21. Important differences between human and mouse APOE gene promoters: limitation of mouse APOE model in studying Alzheimer's disease.
Maloney B; Ge YW; Alley GM; Lahiri DK
J Neurochem; 2007 Nov; 103(3):1237-57. PubMed ID: 17854398
[TBL] [Abstract][Full Text] [Related]
22. Clearance of Alzheimer's Abeta peptide: the many roads to perdition.
Tanzi RE; Moir RD; Wagner SL
Neuron; 2004 Sep; 43(5):605-8. PubMed ID: 15339642
[TBL] [Abstract][Full Text] [Related]
23. Elevated plasma cholesterol does not affect brain Abeta in mice lacking the low-density lipoprotein receptor.
Elder GA; Cho JY; English DF; Franciosi S; Schmeidler J; Sosa MA; Gasperi RD; Fisher EA; Mathews PM; Haroutunian V; Buxbaum JD
J Neurochem; 2007 Aug; 102(4):1220-31. PubMed ID: 17472705
[TBL] [Abstract][Full Text] [Related]
24. [Advances in molecular biology and clinical study of amyloid precursor protein for Alzheimer's disease].
Xu BG; Wu X
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Apr; 26(2):201-9. PubMed ID: 15171563
[TBL] [Abstract][Full Text] [Related]
25. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease.
Poirier J
Neurobiol Aging; 2005 Mar; 26(3):355-61. PubMed ID: 15639314
[TBL] [Abstract][Full Text] [Related]
26. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
van Groen T; Kiliaan AJ; Kadish I
Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
[TBL] [Abstract][Full Text] [Related]
27. Matrix metalloproteinase 3 haplotypes and plasma amyloid beta levels: the Rotterdam Study.
Reitz C; van Rooij FJ; Soares HD; de Maat MP; Hofman A; Witteman JC; Breteler MM
Neurobiol Aging; 2010 Apr; 31(4):715-8. PubMed ID: 18606478
[TBL] [Abstract][Full Text] [Related]
28. Heritability of plasma amyloid beta in typical late-onset Alzheimer's disease pedigrees.
Ertekin-Taner N; Graff-Radford N; Younkin LH; Eckman C; Adamson J; Schaid DJ; Blangero J; Hutton M; Younkin SG
Genet Epidemiol; 2001 Jul; 21(1):19-30. PubMed ID: 11443731
[TBL] [Abstract][Full Text] [Related]
29. Altered apolipoprotein E glycosylation is associated with Abeta(42) accumulation in an animal model of Niemann-Pick Type C disease.
Chua CC; Lim ML; Wong BS
J Neurochem; 2010 Mar; 112(6):1619-26. PubMed ID: 20070866
[TBL] [Abstract][Full Text] [Related]
30. Inflammation, genes and zinc in Alzheimer's disease.
Vasto S; Candore G; Listì F; Balistreri CR; Colonna-Romano G; Malavolta M; Lio D; Nuzzo D; Mocchegiani E; Di Bona D; Caruso C
Brain Res Rev; 2008 Jun; 58(1):96-105. PubMed ID: 18190968
[TBL] [Abstract][Full Text] [Related]
31. Cerebral small vessel disease-induced apolipoprotein E leakage is associated with Alzheimer disease and the accumulation of amyloid beta-protein in perivascular astrocytes.
Utter S; Tamboli IY; Walter J; Upadhaya AR; Birkenmeier G; Pietrzik CU; Ghebremedhin E; Thal DR
J Neuropathol Exp Neurol; 2008 Sep; 67(9):842-56. PubMed ID: 18716559
[TBL] [Abstract][Full Text] [Related]
32. The pathological cross talk between apolipoprotein E and amyloid-beta peptide in Alzheimer's disease: emerging gene-based therapeutic approaches.
Iurescia S; Fioretti D; Mangialasche F; Rinaldi M
J Alzheimers Dis; 2010; 21(1):35-48. PubMed ID: 20182014
[TBL] [Abstract][Full Text] [Related]
33. Apolipoprotein E co-localizes with newly formed amyloid beta-protein (Abeta) deposits lacking immunoreactivity against N-terminal epitopes of Abeta in a genotype-dependent manner.
Thal DR; Capetillo-Zarate E; Schultz C; Rüb U; Saido TC; Yamaguchi H; Haass C; Griffin WS; Del Tredici K; Braak H; Ghebremedhin E
Acta Neuropathol; 2005 Nov; 110(5):459-71. PubMed ID: 16195918
[TBL] [Abstract][Full Text] [Related]
34. ApoE: crossroads between Alzheimer's disease and atherosclerosis.
Stojakovic T; Scharnagl H; März W
Semin Vasc Med; 2004 Aug; 4(3):279-85. PubMed ID: 15630629
[TBL] [Abstract][Full Text] [Related]
35. Redox proteomics identification of oxidatively modified proteins in Alzheimer's disease brain and in vivo and in vitro models of AD centered around Abeta(1-42).
Sultana R; Perluigi M; Butterfield DA
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Mar; 833(1):3-11. PubMed ID: 16236561
[TBL] [Abstract][Full Text] [Related]
36. Brain lipid metabolism, apolipoprotein E and the pathophysiology of Alzheimer's disease.
Bales KR
Neuropharmacology; 2010; 59(4-5):295-302. PubMed ID: 20079752
[TBL] [Abstract][Full Text] [Related]
37. High dietary consumption of trans fatty acids decreases brain docosahexaenoic acid but does not alter amyloid-beta and tau pathologies in the 3xTg-AD model of Alzheimer's disease.
Phivilay A; Julien C; Tremblay C; Berthiaume L; Julien P; Giguère Y; Calon F
Neuroscience; 2009 Mar; 159(1):296-307. PubMed ID: 19135506
[TBL] [Abstract][Full Text] [Related]
38. Apolipoprotein gene and its interaction with the environmentally driven risk factors: molecular, genetic and epidemiological studies of Alzheimer's disease.
Lahiri DK; Sambamurti K; Bennett DA
Neurobiol Aging; 2004; 25(5):651-60. PubMed ID: 15172744
[TBL] [Abstract][Full Text] [Related]
39. Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease.
Gouras GK; Almeida CG; Takahashi RH
Neurobiol Aging; 2005 Oct; 26(9):1235-44. PubMed ID: 16023263
[TBL] [Abstract][Full Text] [Related]
40. Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease.
Huang Y
Trends Mol Med; 2010 Jun; 16(6):287-94. PubMed ID: 20537952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
